WANY
CRDL

Wealthspire Advisors (New York)’s Cardiol Therapeutics CRDL Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.5K Hold
15,151
– – ﹤0.01% 924
2025
Q4 		$14.5K Buy
+15,151
New +$15.9K ﹤0.01% 1032
2025
Q3 		– Sell
-15,151
Closed -$20.6K – 3063
2025
Q2 		$20.6K Hold
15,151
– – ﹤0.01% 843
2025
Q1 		$14.7K Hold
15,151
– – ﹤0.01% 785
2024
Q4 		$19.4K Sell
15,151
-15,151
-50% -$25.5K ﹤0.01% 789
2024
Q3 		$60K Buy
+30,302
New +$62.9K ﹤0.01% 737

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wealthspire Advisors (New York)'s CRDL Position: Q1 2026 in Review

Wealthspire Advisors (New York) held its Cardiol Therapeutics (CRDL) position steady in Q1 2026 at 15,151 shares worth $20.5K. The position accounts for ﹤0.01% of the portfolio, ranked #924.

Wealthspire Advisors (New York) first reported a position in CRDL in Q3 2024 and has held it in 6 quarters since. The position peaked at $60K in Q3 2024. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Wealthspire Advisors (New York) held 15,151 shares of Cardiol Therapeutics worth $20.5K as of Q1 2026.
  • Wealthspire Advisors (New York) left its Cardiol Therapeutics share count unchanged in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q1 2026, its #924 holding.
  • Wealthspire Advisors (New York) first reported a position in Cardiol Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Wealthspire Advisors (New York)'s Cardiol Therapeutics position peaked at $60K in Q3 2024.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2026, filed 1 May 2026.